Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Department of Pathology and Molecular Medicine, |
RCV000496718 | SCV000588043 | uncertain significance | not specified | 2017-04-20 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000579719 | SCV000683089 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-05-15 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000691894 | SCV000819692 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2024-01-14 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 1052 of the BRCA1 protein (p.Asn1052Ser). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 91606). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000579719 | SCV001180127 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-05-06 | criteria provided, single submitter | clinical testing | The p.N1052S variant (also known as c.3155A>G), located in coding exon 9 of the BRCA1 gene, results from an A to G substitution at nucleotide position 3155. The asparagine at codon 1052 is replaced by serine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000496718 | SCV002050795 | uncertain significance | not specified | 2021-12-06 | criteria provided, single submitter | clinical testing | |
University of Washington Department of Laboratory Medicine, |
RCV000579719 | SCV003847288 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003477479 | SCV004219339 | uncertain significance | not provided | 2023-05-04 | criteria provided, single submitter | clinical testing | This variant has not been reported in the published literature in individuals with BRCA1-related cancers. It also has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant. |
Sharing Clinical Reports Project |
RCV000077123 | SCV000108920 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2013-05-29 | no assertion criteria provided | clinical testing |